ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,303.27
0.12%
US Tech 100
18,062.00
-0.10%
다우존스 지수
40,003.59
0.34%
Bitcoin
67,278.85
0.30%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. CASI Pharmaceuticals Inc (CASI)

  7. CASI Pharmaceuticals Inc (CASI) 뉴스

CASI

CASI Pharmaceuticals (CASI)

CASI Pharmaceuticals Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:CASI
일자시간출처헤드라인심볼기업
2024/05/1521:00PR Newswire (US)CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)NASDAQ:CASICASI Pharmaceuticals Inc
2024/05/1519:50Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CASICASI Pharmaceuticals Inc
2024/05/1421:00PR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTSNASDAQ:CASICASI Pharmaceuticals Inc
2024/05/1313:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CASICASI Pharmaceuticals Inc
2024/04/0906:00PR Newswire (US)CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTASNASDAQ:CASICASI Pharmaceuticals Inc
2024/03/2820:00PR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTSNASDAQ:CASICASI Pharmaceuticals Inc
2024/03/0521:00PR Newswire (US)CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In ChinaNASDAQ:CASICASI Pharmaceuticals Inc
2024/02/1621:00PR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINANASDAQ:CASICASI Pharmaceuticals Inc
2023/11/1421:00PR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATESNASDAQ:CASICASI Pharmaceuticals Inc
2023/11/0821:00PR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPANASDAQ:CASICASI Pharmaceuticals Inc
2023/08/1120:00PR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATESNASDAQ:CASICASI Pharmaceuticals Inc
2023/08/0120:00PR Newswire (US)Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI PharmaceuticalsNASDAQ:CASICASI Pharmaceuticals Inc
2023/07/2021:00PR Newswire (US)CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339NASDAQ:CASICASI Pharmaceuticals Inc
2023/05/1720:35PR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTSNASDAQ:CASICASI Pharmaceuticals Inc
2023/04/2622:49PR Newswire (US)CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022NASDAQ:CASICASI Pharmaceuticals Inc
2023/04/2621:27Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:CASICASI Pharmaceuticals Inc
2023/04/2620:00PR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTSNASDAQ:CASICASI Pharmaceuticals Inc
2023/03/2219:04Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:CASICASI Pharmaceuticals Inc
2023/03/2206:08Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:CASICASI Pharmaceuticals Inc
2023/03/2205:51Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:CASICASI Pharmaceuticals Inc
2023/03/2205:42Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CASICASI Pharmaceuticals Inc
2023/03/2205:30PR Newswire (US)CASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGERNASDAQ:CASICASI Pharmaceuticals Inc
2023/02/1000:49Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CASICASI Pharmaceuticals Inc
2023/02/0200:40Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CASICASI Pharmaceuticals Inc
2023/02/0106:02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CASICASI Pharmaceuticals Inc
2023/01/0621:00PR Newswire (US)CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINANASDAQ:CASICASI Pharmaceuticals Inc
2022/12/1521:00PR Newswire (US)CASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG APPLICATION FOR CNCT19 ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATIONNASDAQ:CASICASI Pharmaceuticals Inc
2022/11/1616:57TipRanksBTIG Sticks to Their Buy Rating for CASI Pharmaceuticals (CASI)NASDAQ:CASICASI Pharmaceuticals Inc
2022/11/1506:04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CASICASI Pharmaceuticals Inc
2022/11/1421:00PR Newswire (US)CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTSNASDAQ:CASICASI Pharmaceuticals Inc
 검색 관련기사 보기:NASDAQ:CASI

최근 히스토리

ASX
MFGKOR
MRTX
TVNTETH
TravelNote
COIN
SSXGBP
AMEX
SZX
GATE
BIFIUSDT
KOSPI
610063
Kis CD Rate ETN 63
USOTC
RDBBF
Articore (PK)
NASDAQ
UPCS
Ubiquitel
BIT
MDA
Lyxor Index Fund-lyxor S...
LSE
TNP
GDAX
PONDUSD
Marlin
BIT
F19792
Vontobel Financial Produ...
EU
HSBCJ
Hsbc Bank France 0.677% ...
NYSE
AQNU
Algonquin Power and Util...
TSXV
FRN
Feronia
COIN
MBNNBTC
Mobilian
Delayed Upgrade Clock
ADVFN Logo

대한민국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유